Exciting New Collaboration in AI Drug Discovery
Lifespan Vision Ventures is pleased to announce that its portfolio company, Algen Biotechnologies, has entered into a groundbreaking collaboration with AstraZeneca. This partnership marks a significant advancement in the realm of AI-driven drug discovery, particularly in the field of immunology.
Combining Expertise for a Better Future
The partnership aims to merge Algen's innovative functional genomics and machine learning technologies with AstraZeneca's profound scientific knowledge and extensive research and development capabilities. By doing so, both companies aspire to discover and validate new therapeutic targets, focusing on immune-mediated and inflammatory diseases.
Transformative Goals
The ultimate goal of this collaboration is to fast-track the development of next-generation medicines that can significantly enhance patient care.
Key Highlights from Lifespan Vision Ventures
Harry Robb, Principal at Lifespan Vision Ventures, expressed his enthusiasm about Algen Biotechnologies reaching this pivotal milestone. He commented on the originality of Algen's platform that seamlessly combines CRISPR-based functional screening with advanced AI analytics, which allows for the exploration of disease-relevant biology on a large scale. This partnership with AstraZeneca highlights the outstanding quality of Algen's technology and its transformative potential within drug discovery.
A Committed Investor
Lifespan Vision Ventures has taken an early investment stance in Algen Biotechnologies, fully supporting its mission to develop transformative therapies aimed at improving outcomes in age-related diseases while also working to extend healthspan.
About Algen Biotechnologies
Algen Biotechnologies is leading the way in the creation of precision therapeutics by reshaping the drug discovery process through the fusion of CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang and Christine Du, Algen emerged as a spin-off from the esteemed lab of Nobel laureate Jennifer Doudna at UC Berkeley. The company harnesses deep learning and high-throughput functional genomics to identify revolutionary therapeutic targets.
Innovative Platform
Algen’s proprietary platform, AlgenBrain™, combines cutting-edge computational models with scalable, single-cell experimental systems. This integration enables the decoding of causal disease biology, accelerating the journey toward the development of innovative therapies. The company proudly operates from San Francisco, CA.
About Lifespan Vision Ventures
Lifespan Vision Ventures is an international venture capital firm committed to investing in early-stage biotechnology and longevity companies that are creating revolutionary technologies. Their mission centers on developing solutions that address age-related diseases and promote healthy aging.
Contact Information
For inquiries or more information about Algen Biotechnologies, feel free to reach out via email, but please note that the exact email has been omitted for privacy and security reasons.
Frequently Asked Questions
What is the purpose of the collaboration between Algen and AstraZeneca?
The collaboration aims to advance AI-powered drug discovery, specifically targeting immune-mediated and inflammatory diseases.
What technology does Algen Biotechnologies use?
Algen utilizes a combination of CRISPR gene modulation and advanced AI analytics for drug discovery.
Who founded Algen Biotechnologies?
Algen was founded by Chun-Hao Huang and Christine Du, stemming from research at the lab of Jennifer Doudna.
What is the goal of Lifespan Vision Ventures?
Lifespan Vision Ventures aims to invest in companies developing breakthrough technologies to prevent and treat age-related diseases.
Where is Algen Biotechnologies headquartered?
Algen Biotechnologies is headquartered in San Francisco, CA.
